ID   RIPK1_HUMAN             Reviewed;         671 AA.
AC   Q13546; A0AV89; B2RAG1; B4E3F9; Q13180; Q59H33;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 3.
DT   10-MAY-2017, entry version 185.
DE   RecName: Full=Receptor-interacting serine/threonine-protein kinase 1;
DE            EC=2.7.11.1;
DE   AltName: Full=Cell death protein RIP;
DE   AltName: Full=Receptor-interacting protein 1;
DE            Short=RIP-1;
DE   AltName: Full=Serine/threonine-protein kinase RIP;
GN   Name=RIPK1; Synonyms=RIP, RIP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AUTOPHOSPHORYLATION,
RP   MUTAGENESIS OF LYS-45, INTERACTION WITH TRADD; TRAF1; TRAF2 AND TRAF3,
RP   AND VARIANT VAL-438.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=8612133; DOI=10.1016/S1074-7613(00)80252-6;
RA   Hsu H., Huang J., Shu H.-B., Baichwal V.R., Goeddel D.V.;
RT   "TNF-dependent recruitment of the protein kinase RIP to the TNF
RT   receptor-1 signaling complex.";
RL   Immunity 4:387-396(1996).
RN   [2]
RP   SEQUENCE REVISION TO 120.
RA   Huang J., Hsu H., Baichwal V.R., Goeddel D.V.;
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 15-671 (ISOFORM 2).
RC   TISSUE=Adrenal gland, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-234.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   VAL-438.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-671.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 300-671, AND VARIANT VAL-438.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=7538908; DOI=10.1016/0092-8674(95)90072-1;
RA   Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.;
RT   "RIP: a novel protein containing a death domain that interacts with
RT   Fas/APO-1 (CD95) in yeast and causes cell death.";
RL   Cell 81:513-523(1995).
RN   [9]
RP   CLEAVAGE BY CASPASE-8, AND MUTAGENESIS OF ASP-324.
RX   PubMed=10521396; DOI=10.1101/gad.13.19.2514;
RA   Lin Y., Devin A., Rodriguez Y., Liu Z.-G.;
RT   "Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-
RT   induced apoptosis.";
RL   Genes Dev. 13:2514-2526(1999).
RN   [10]
RP   INTERACTION WITH SQSTM1 AND TRAF2, AND DOMAIN.
RX   PubMed=10356400; DOI=10.1093/emboj/18.11.3044;
RA   Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.;
RT   "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB
RT   activation.";
RL   EMBO J. 18:3044-3053(1999).
RN   [11]
RP   INTERACTION WITH RIPK3.
RX   PubMed=10358032; DOI=10.1074/jbc.274.24.16871;
RA   Sun X., Lee J., Navas T., Baldwin D.T., Stewart T.A., Dixit V.M.;
RT   "RIP3, a novel apoptosis-inducing kinase.";
RL   J. Biol. Chem. 274:16871-16875(1999).
RN   [12]
RP   INTERACTION WITH BNLF1.
RX   PubMed=10409763; DOI=10.1128/MCB.19.8.5759;
RA   Izumi K.M., Cahir McFarland E., Ting A.T., Riley E.A., Seed B.,
RA   Kieff E.D.;
RT   "The Epstein-Barr virus oncoprotein latent membrane protein 1 engages
RT   the tumor necrosis factor receptor-associated proteins TRADD and
RT   receptor-interacting protein (RIP) but does not induce apoptosis or
RT   require RIP for NF-kappaB activation.";
RL   Mol. Cell. Biol. 19:5759-5767(1999).
RN   [13]
RP   INTERACTION WITH IKBKG.
RX   PubMed=9927690; DOI=10.1073/pnas.96.3.1042;
RA   Li Y., Kang J., Friedman J., Tarassishin L., Ye J., Kovalenko A.,
RA   Wallach D., Horwitz M.S.;
RT   "Identification of a cell protein (FIP-3) as a modulator of NF-kappaB
RT   activity and as a target of an adenovirus inhibitor of tumor necrosis
RT   factor alpha-induced apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1042-1047(1999).
RN   [14]
RP   FUNCTION.
RX   PubMed=11101870; DOI=10.1038/82732;
RA   Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S.,
RA   Bodmer J.L., Schneider P., Seed B., Tschopp J.;
RT   "Fas triggers an alternative, caspase-8-independent cell death pathway
RT   using the kinase RIP as effector molecule.";
RL   Nat. Immunol. 1:489-495(2000).
RN   [15]
RP   INTERACTION WITH EGFR.
RX   PubMed=11116146; DOI=10.1074/jbc.M008458200;
RA   Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S.,
RA   Vartanian T.;
RT   "The epidermal growth factor receptor engages receptor interacting
RT   protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to
RT   activate NF-kappa B. Identification of a novel receptor-tyrosine
RT   kinase signalosome.";
RL   J. Biol. Chem. 276:8865-8874(2001).
RN   [16]
RP   INTERACTION WITH RNF216.
RX   PubMed=11854271; DOI=10.1074/jbc.M108675200;
RA   Chen D., Li X., Zhai Z., Shu H.-B.;
RT   "A novel zinc finger protein interacts with receptor-interacting
RT   protein (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-
RT   induced NF-kappa B activation.";
RL   J. Biol. Chem. 277:15985-15991(2002).
RN   [17]
RP   RIP HOMOTYPIC INTERACTION MOTIF, AND INTERACTION WITH RIPK3.
RX   PubMed=11734559; DOI=10.1074/jbc.M109488200;
RA   Sun X., Yin J., Starovasnik M.A., Fairbrother W.J., Dixit V.M.;
RT   "Identification of a novel homotypic interaction motif required for
RT   the phosphorylation of receptor-interacting protein (RIP) by RIP3.";
RL   J. Biol. Chem. 277:9505-9511(2002).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-384, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [19]
RP   INTERACTION WITH ZFAND5.
RX   PubMed=14754897; DOI=10.1074/jbc.M309491200;
RA   Huang J., Teng L., Li L., Liu T., Li L., Chen D., Xu L.-G., Zhai Z.,
RA   Shu H.-B.;
RT   "ZNF216 is an A20-like and IkappaB kinase gamma-interacting inhibitor
RT   of NFkappaB activation.";
RL   J. Biol. Chem. 279:16847-16853(2004).
RN   [20]
RP   UBIQUITINATION BY TRAF2, AND DEUBIQUITINATION BY TNFAIP3.
RX   PubMed=15258597; DOI=10.1038/nature02794;
RA   Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S.,
RA   Wu P., Wiesmann C., Baker R., Boone D.L., Ma A., Koonin E.V.,
RA   Dixit V.M.;
RT   "De-ubiquitination and ubiquitin ligase domains of A20 downregulate
RT   NF-kappaB signalling.";
RL   Nature 430:694-699(2004).
RN   [21]
RP   INTERACTION WITH MAVS.
RX   PubMed=16127453; DOI=10.1038/ni1243;
RA   Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H.,
RA   Ishii K.J., Takeuchi O., Akira S.;
RT   "IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I
RT   interferon induction.";
RL   Nat. Immunol. 6:981-988(2005).
RN   [22]
RP   UBIQUITINATION AT LYS-377, AND MUTAGENESIS OF LYS-377.
RX   PubMed=16603398; DOI=10.1016/j.molcel.2006.03.026;
RA   Ea C.K., Deng L., Xia Z.P., Pineda G., Chen Z.J.;
RT   "Activation of IKK by TNFalpha requires site-specific ubiquitination
RT   of RIP1 and polyubiquitin binding by NEMO.";
RL   Mol. Cell 22:245-257(2006).
RN   [23]
RP   REVIEW.
RX   PubMed=17301840; DOI=10.1038/sj.cdd.4402085;
RA   Festjens N., Vanden Berghe T., Cornelis S., Vandenabeele P.;
RT   "RIP1, a kinase on the crossroads of a cell's decision to live or
RT   die.";
RL   Cell Death Differ. 14:400-410(2007).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF DAB2IP, AND INTERACTION WITH DAB2IP.
RX   PubMed=17389591; DOI=10.1074/jbc.M701148200;
RA   Zhang H., Zhang H., Lin Y., Li J., Pober J.S., Min W.;
RT   "RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is
RT   critical for tumor necrosis factor-induced ASK1-JNK/p38 activation.";
RL   J. Biol. Chem. 282:14788-14796(2007).
RN   [25]
RP   INTERACTION WITH RBCK1.
RX   PubMed=17449468; DOI=10.1074/jbc.M701913200;
RA   Tian Y., Zhang Y., Zhong B., Wang Y.Y., Diao F.C., Wang R.P.,
RA   Zhang M., Chen D.Y., Zhai Z.H., Shu H.B.;
RT   "RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-
RT   triggered NF-kappaB activation by targeting TAB2/3 for degradation.";
RL   J. Biol. Chem. 282:16776-16782(2007).
RN   [26]
RP   INTERACTION WITH RFFL, AND UBIQUITINATION BY RFFL.
RX   PubMed=18450452; DOI=10.1016/j.cub.2008.04.017;
RA   Liao W., Xiao Q., Tchikov V., Fujita K., Yang W., Wincovitch S.,
RA   Garfield S., Conze D., El-Deiry W.S., Schuetze S., Srinivasula S.M.;
RT   "CARP-2 is an endosome-associated ubiquitin ligase for RIP and
RT   regulates TNF-induced NF-kappaB activation.";
RL   Curr. Biol. 18:641-649(2008).
RN   [27]
RP   MUTAGENESIS OF SER-161, INHIBITION BY NECROSTATIN-1, AND
RP   PHOSPHORYLATION AT SER-6; SER-20; SER-25; SER-161; SER-166; SER-303;
RP   SER-320 AND SER-333.
RX   PubMed=18408713; DOI=10.1038/nchembio.83;
RA   Degterev A., Hitomi J., Germscheid M., Ch'en I.L., Korkina O.,
RA   Teng X., Abbott D., Cuny G.D., Yuan C., Wagner G., Hedrick S.M.,
RA   Gerber S.A., Lugovskoy A., Yuan J.;
RT   "Identification of RIP1 kinase as a specific cellular target of
RT   necrostatins.";
RL   Nat. Chem. Biol. 4:313-321(2008).
RN   [28]
RP   INTERACTION WITH MURID HERPESVIRUS 1 VIRAL INHIBITOR OF RIP
RP   ACTIVATION.
RX   PubMed=18442983; DOI=10.1074/jbc.C800051200;
RA   Upton J.W., Kaiser W.J., Mocarski E.S.;
RT   "Cytomegalovirus M45 cell death suppression requires receptor-
RT   interacting protein (RIP) homotypic interaction motif (RHIM)-dependent
RT   interaction with RIP1.";
RL   J. Biol. Chem. 283:16966-16970(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [30]
RP   FUNCTION, AND PHOSPHORYLATION.
RX   PubMed=19524513; DOI=10.1016/j.cell.2009.05.037;
RA   Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M.,
RA   Chan F.K.;
RT   "Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates
RT   programmed necrosis and virus-induced inflammation.";
RL   Cell 137:1112-1123(2009).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH RIPK3.
RX   PubMed=19524512; DOI=10.1016/j.cell.2009.05.021;
RA   He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X.;
RT   "Receptor interacting protein kinase-3 determines cellular necrotic
RT   response to TNF-alpha.";
RL   Cell 137:1100-1111(2009).
RN   [32]
RP   INTERACTION WITH RNF34, AND UBIQUITINATION BY RNF34.
RX   DOI=10.1016/j.cub.2008.11.041;
RA   Liao W., Fujita K., Xiao Q., Tchikov V., Yang W., Gunsor M.,
RA   Garfield S., Goldsmith P., El-Deiry W.S., Schuetze S.,
RA   Srinivasula S.M.;
RT   "Response: CARP1 regulates induction of NF-kappaB by TNFalpha.";
RL   Curr. Biol. 19:R17-R19(2009).
RN   [33]
RP   REVIEW.
RX   PubMed=20354226; DOI=10.1126/scisignal.3115re4;
RA   Vandenabeele P., Declercq W., Van Herreweghe F., Vanden Berghe T.;
RT   "The role of the kinases RIP1 and RIP3 in TNF-induced necrosis.";
RL   Sci. Signal. 3:RE4-RE4(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   UBIQUITINATION BY THE LUBAC COMPLEX.
RX   PubMed=21455173; DOI=10.1038/nature09816;
RA   Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E.,
RA   Haas T.L., Webb A.I., Rickard J.A., Anderton H., Wong W.W.,
RA   Nachbur U., Gangoda L., Warnken U., Purcell A.W., Silke J.,
RA   Walczak H.;
RT   "Linear ubiquitination prevents inflammation and regulates immune
RT   signalling.";
RL   Nature 471:591-596(2011).
RN   [36]
RP   UBIQUITINATION BY BIRC2/C-IAP1 AND BIRC3/C-IAP2, AND INTERACTION WITH
RP   BIRC2/C-IAP1; BIRC3/C-IAP2 AND XIAP/BIRC4.
RX   PubMed=21931591; DOI=10.1371/journal.pone.0022356;
RA   Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R.,
RA   De Medts J., Gevaert K., Declercq W., Vandenabeele P.;
RT   "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin
RT   chains to receptor interacting proteins kinases 1 to 4 (RIP1-4).";
RL   PLoS ONE 6:E22356-E22356(2011).
RN   [37]
RP   IDENTIFICATION IN COMPLEX WITH PGAM5; RIPK3 AND MLKL.
RX   PubMed=22265414; DOI=10.1016/j.cell.2011.11.030;
RA   Wang Z., Jiang H., Chen S., Du F., Wang X.;
RT   "The mitochondrial phosphatase PGAM5 functions at the convergence
RT   point of multiple necrotic death pathways.";
RL   Cell 148:228-243(2012).
RN   [38]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=21887730; DOI=10.1002/ibd.21851;
RA   Zhao Y., Alonso C., Ballester I., Song J.H., Chang S.Y., Guleng B.,
RA   Arihiro S., Murray P.J., Xavier R., Kobayashi K.S., Reinecker H.C.;
RT   "Control of NOD2 and Rip2-dependent innate immune activation by GEF-
RT   H1.";
RL   Inflamm. Bowel Dis. 18:603-612(2012).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [41]
RP   INTERACTION WITH TICAM1.
RX   PubMed=25736436; DOI=10.15252/embr.201439637;
RA   Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B.,
RA   Liu Y.;
RT   "WDFY1 mediates TLR3/4 signaling by recruiting TRIF.";
RL   EMBO Rep. 16:447-455(2015).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-294 IN COMPLEXES WITH
RP   NECROSTATIN-TYPE INHIBITORS, CATALYTIC ACTIVITY, ENZYME REGULATION,
RP   AND AUTOPHOSPHORYLATION.
RX   PubMed=23473668; DOI=10.1016/j.str.2013.01.016;
RA   Xie T., Peng W., Liu Y., Yan C., Maki J., Degterev A., Yuan J.,
RA   Shi Y.;
RT   "Structural basis of RIP1 inhibition by necrostatins.";
RL   Structure 21:493-499(2013).
RN   [43]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-64; ILE-81; VAL-220; SER-404;
RP   VAL-443 AND VAL-569.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine-threonine kinase which transduces inflammatory
CC       and cell-death signals (programmed necrosis) following death
CC       receptors ligation, activation of pathogen recognition receptors
CC       (PRRs), and DNA damage. Upon activation of TNFR1 by the TNF-alpha
CC       family cytokines, TRADD and TRAF2 are recruited to the receptor.
CC       Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependent
CC       manner, and thereby activates the MAP3K5-JNK apoptotic cascade.
CC       Ubiquitination by TRAF2 via 'Lys-63'-link chains acts as a
CC       critical enhancer of communication with downstream signal
CC       transducers in the mitogen-activated protein kinase pathway and
CC       the NF-kappa-B pathway, which in turn mediate downstream events
CC       including the activation of genes encoding inflammatory molecules.
CC       Polyubiquitinated protein binds to IKBKG/NEMO, the regulatory
CC       subunit of the IKK complex, a critical event for NF-kappa-B
CC       activation. Interaction with other cellular RHIM-containing
CC       adapters initiates gene activation and cell death. RIPK1 and RIPK3
CC       association, in particular, forms a necrosis-inducing complex.
CC       {ECO:0000269|PubMed:11101870, ECO:0000269|PubMed:17389591,
CC       ECO:0000269|PubMed:19524512, ECO:0000269|PubMed:19524513}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:23473668}.
CC   -!- ENZYME REGULATION: Inhibited by necrostatins, including
CC       necrostatin-1, necrostatin-3 and necrostatin-4.
CC       {ECO:0000269|PubMed:23473668}.
CC   -!- SUBUNIT: Interacts (via RIP homotypic interaction motif) with
CC       RIPK3 (via RIP homotypic interaction motif). Upon TNF-induced
CC       necrosis, the RIPK1-RIPK3 dimer further interacts with PGAM5 and
CC       MLKL; the formation of this complex leads to PGAM5 phosphorylation
CC       and increase in PGAM5 phosphatase activity. Interacts (via the
CC       death domain) with TNFRSF6 (via the death domain) and TRADD (via
CC       the death domain). Is recruited by TRADD to TNFRSF1A in a TNF-
CC       dependent process. Binds RNF216, EGFR, IKBKG, TRAF1, TRAF2 and
CC       TRAF3. Interacts with BNLF1. Interacts with SQSTM1 upon TNF-alpha
CC       stimulation. May interact with MAVS/IPS1. Interacts with ZFAND5.
CC       Interacts with RBCK1 (By similarity). Interacts with ZBP1 (By
CC       similarity). Interacts with BIRC2/c-IAP1, BIRC3/c-IAP2 and
CC       XIAP/BIRC4. Upon TNF-induced necrosis, forms in complex with
CC       PGAM5, RIPK3 and MLKL. Interacts (via kinase domain) with DAB2IP
CC       (via Ras-GAP domain); the interaction occurs in a TNF-alpha-
CC       dependent manner. Interacts with ARHGEF2. Interacts (via protein
CC       kinase domain) with RFFL; involved in RIPK1 ubiquitination.
CC       Interacts with RNF34; involved in RIPK1 ubiquitination. Interacts
CC       with TICAM1 and this interaction is enhanced in the presence of
CC       WDFY1 (PubMed:25736436). {ECO:0000250|UniProtKB:Q60855,
CC       ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:10358032,
CC       ECO:0000269|PubMed:10409763, ECO:0000269|PubMed:11116146,
CC       ECO:0000269|PubMed:11734559, ECO:0000269|PubMed:11854271,
CC       ECO:0000269|PubMed:14754897, ECO:0000269|PubMed:16127453,
CC       ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:17449468,
CC       ECO:0000269|PubMed:18442983, ECO:0000269|PubMed:18450452,
CC       ECO:0000269|PubMed:19524512, ECO:0000269|PubMed:21887730,
CC       ECO:0000269|PubMed:21931591, ECO:0000269|PubMed:22265414,
CC       ECO:0000269|PubMed:25736436, ECO:0000269|PubMed:8612133,
CC       ECO:0000269|PubMed:9927690, ECO:0000269|Ref.32}.
CC   -!- INTERACTION:
CC       Self; NbExp=8; IntAct=EBI-358507, EBI-358507;
CC       P04083:ANXA1; NbExp=5; IntAct=EBI-358507, EBI-354007;
CC       Q13490:BIRC2; NbExp=3; IntAct=EBI-358507, EBI-514538;
CC       Q13489:BIRC3; NbExp=3; IntAct=EBI-358507, EBI-517709;
CC       Q92851:CASP10; NbExp=2; IntAct=EBI-358507, EBI-495095;
CC       Q14790:CASP8; NbExp=24; IntAct=EBI-358507, EBI-78060;
CC       Q8IVM0:CCDC50; NbExp=2; IntAct=EBI-358507, EBI-723996;
CC       P48729:CSNK1A1; NbExp=5; IntAct=EBI-358507, EBI-1383726;
CC       Q13158:FADD; NbExp=9; IntAct=EBI-358507, EBI-494804;
CC       Q9Y6K9:IKBKG; NbExp=7; IntAct=EBI-358507, EBI-81279;
CC       Q9ULZ3:PYCARD; NbExp=2; IntAct=EBI-358507, EBI-751215;
CC       Q9Y572:RIPK3; NbExp=26; IntAct=EBI-358507, EBI-298250;
CC       Q9QZL0:Ripk3 (xeno); NbExp=2; IntAct=EBI-358507, EBI-2367423;
CC       P19438:TNFRSF1A; NbExp=6; IntAct=EBI-358507, EBI-299451;
CC       Q13077:TRAF1; NbExp=5; IntAct=EBI-358507, EBI-359224;
CC       Q12933:TRAF2; NbExp=6; IntAct=EBI-358507, EBI-355744;
CC       U5TQE9:UL39 (xeno); NbExp=3; IntAct=EBI-358507, EBI-11894787;
CC       Q13107:USP4; NbExp=4; IntAct=EBI-358507, EBI-723290;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13546-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13546-2; Sequence=VSP_037690;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: Contains a C-terminal death domain (DD) that engages other
CC       DD-containing proteins as well as a central (intermediate) region
CC       important for NF-kB activation and RHIM-dependent signaling.
CC       {ECO:0000269|PubMed:10356400}.
CC   -!- PTM: Proteolytically cleaved by caspase-8 during TNF-induced
CC       apoptosis. Cleavage abolishes NF-kappa-B activation and enhances
CC       pro-apoptotic signaling through the TRADD-FADD interaction.
CC       {ECO:0000269|PubMed:10521396}.
CC   -!- PTM: RIPK1 and RIPK3 undergo reciprocal auto- and trans-
CC       phosphorylation. Phosphorylation of Ser-161 by RIPK3 is necessary
CC       for the formation of the necroptosis-inducing complex.
CC       {ECO:0000269|PubMed:18408713, ECO:0000269|PubMed:19524513}.
CC   -!- PTM: Ubiquitinated by 'Lys-11'-, 'Lys-48'-, 'Lys-63'- and linear-
CC       linked type ubiquitin. Polyubiquitination with 'Lys-63'-linked
CC       chains by TRAF2 induces association with the IKK complex.
CC       Deubiquitination of 'Lys-63'-linked chains and polyubiquitination
CC       with 'Lys-48'-linked chains by TNFAIP3 leads to RIPK1 proteasomal
CC       degradation and consequently down-regulates TNF-alpha-induced
CC       NFkappa-B signaling. 'Lys-48'-linked polyubiquitination by RFFL or
CC       RNF34 also promotes proteasomal degradation and negatively
CC       regulates TNF-alpha-induced NFkappa-B signaling. Linear
CC       polyubiquitinated; the head-to-tail polyubiquitination is mediated
CC       by the LUBAC complex. LPS-mediated activation of NF-kappa-B. Also
CC       ubiquitinated with 'Lys-11'-linked chains. Polyubiquitinated with
CC       'Lys-48' and 'Lys-63'-linked chains by BIRC2/c-IAP1 and BIRC3/c-
CC       IAP2, leading to activation of NF-kappa-B.
CC       {ECO:0000269|PubMed:15258597, ECO:0000269|PubMed:16603398,
CC       ECO:0000269|PubMed:18450452, ECO:0000269|PubMed:21455173,
CC       ECO:0000269|PubMed:21931591, ECO:0000269|Ref.32}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG65471.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ripk1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U50062; AAC32232.1; -; mRNA.
DR   EMBL; AK314176; BAG36858.1; -; mRNA.
DR   EMBL; AK304701; BAG65471.1; ALT_INIT; mRNA.
DR   EMBL; AY682848; AAT74626.1; -; Genomic_DNA.
DR   EMBL; AL031963; CAD70625.1; -; Genomic_DNA.
DR   EMBL; BC126254; AAI26255.1; -; mRNA.
DR   EMBL; BC126256; AAI26257.1; -; mRNA.
DR   EMBL; AB208926; BAD92163.1; -; mRNA.
DR   EMBL; U25994; AAC50137.1; -; mRNA.
DR   CCDS; CCDS4482.1; -. [Q13546-1]
DR   PIR; T09479; T09479.
DR   RefSeq; NP_001303990.1; NM_001317061.1.
DR   RefSeq; NP_003795.2; NM_003804.4. [Q13546-1]
DR   RefSeq; XP_005249514.2; XM_005249457.3. [Q13546-1]
DR   UniGene; Hs.519842; -.
DR   PDB; 4ITH; X-ray; 2.25 A; A/B=1-294.
DR   PDB; 4ITI; X-ray; 2.86 A; A/B=1-294.
DR   PDB; 4ITJ; X-ray; 1.80 A; A/B=1-294.
DR   PDB; 4NEU; X-ray; 2.57 A; A/B=1-324.
DR   PDB; 5HX6; X-ray; 2.23 A; A/B=1-294.
DR   PDBsum; 4ITH; -.
DR   PDBsum; 4ITI; -.
DR   PDBsum; 4ITJ; -.
DR   PDBsum; 4NEU; -.
DR   PDBsum; 5HX6; -.
DR   ProteinModelPortal; Q13546; -.
DR   SMR; Q13546; -.
DR   BioGrid; 114274; 79.
DR   DIP; DIP-433N; -.
DR   IntAct; Q13546; 38.
DR   MINT; MINT-128219; -.
DR   STRING; 9606.ENSP00000259808; -.
DR   BindingDB; Q13546; -.
DR   ChEMBL; CHEMBL5464; -.
DR   GuidetoPHARMACOLOGY; 2189; -.
DR   iPTMnet; Q13546; -.
DR   PhosphoSitePlus; Q13546; -.
DR   BioMuta; RIPK1; -.
DR   DMDM; 60393639; -.
DR   EPD; Q13546; -.
DR   MaxQB; Q13546; -.
DR   PaxDb; Q13546; -.
DR   PeptideAtlas; Q13546; -.
DR   PRIDE; Q13546; -.
DR   DNASU; 8737; -.
DR   Ensembl; ENST00000259808; ENSP00000259808; ENSG00000137275. [Q13546-1]
DR   Ensembl; ENST00000380409; ENSP00000369773; ENSG00000137275. [Q13546-1]
DR   GeneID; 8737; -.
DR   KEGG; hsa:8737; -.
DR   UCSC; uc003mux.4; human. [Q13546-1]
DR   CTD; 8737; -.
DR   DisGeNET; 8737; -.
DR   GeneCards; RIPK1; -.
DR   HGNC; HGNC:10019; RIPK1.
DR   HPA; CAB010302; -.
DR   HPA; HPA015257; -.
DR   MIM; 603453; gene.
DR   neXtProt; NX_Q13546; -.
DR   OpenTargets; ENSG00000137275; -.
DR   PharmGKB; PA34394; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00550000074536; -.
DR   HOGENOM; HOG000010270; -.
DR   HOVERGEN; HBG055612; -.
DR   InParanoid; Q13546; -.
DR   KO; K02861; -.
DR   OMA; VVKRMQS; -.
DR   OrthoDB; EOG091G0479; -.
DR   PhylomeDB; Q13546; -.
DR   TreeFam; TF106506; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-140534; Ligand-dependent caspase activation.
DR   Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-HSA-2562578; TRIF-mediated programmed cell death.
DR   Reactome; R-HSA-3295583; TRP channels.
DR   Reactome; R-HSA-3371378; Regulation by c-FLIP.
DR   Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis.
DR   Reactome; R-HSA-5218900; CASP8 activity is inhibited.
DR   Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-HSA-5675482; Regulation of necroptotic cell death.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-69416; Dimerization of procaspase-8.
DR   Reactome; R-HSA-75893; TNF signaling.
DR   Reactome; R-HSA-933543; NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10.
DR   Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1.
DR   SignaLink; Q13546; -.
DR   SIGNOR; Q13546; -.
DR   ChiTaRS; RIPK1; human.
DR   GeneWiki; RIPK1; -.
DR   GenomeRNAi; 8737; -.
DR   PMAP-CutDB; Q13546; -.
DR   PRO; PR:Q13546; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000137275; -.
DR   CleanEx; HS_RIPK1; -.
DR   ExpressionAtlas; Q13546; baseline and differential.
DR   Genevisible; Q13546; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031264; C:death-inducing signaling complex; IDA:BHF-UCL.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0097342; C:ripoptosome; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0070513; F:death domain binding; IPI:BHF-UCL.
DR   GO; GO:0005123; F:death receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0032403; F:protein complex binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; TAS:Reactome.
DR   GO; GO:0097296; P:activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0007257; P:activation of JUN kinase activity; TAS:BHF-UCL.
DR   GO; GO:1990000; P:amyloid fibril formation; IMP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IMP:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0044257; P:cellular protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0071550; P:death-inducing signaling complex assembly; TAS:Reactome.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; TAS:Reactome.
DR   GO; GO:0070266; P:necroptotic process; IMP:UniProtKB.
DR   GO; GO:0097527; P:necroptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; TAS:Reactome.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0036289; P:peptidyl-serine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:1905206; P:positive regulation of hydrogen peroxide-induced cell death; IMP:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0045651; P:positive regulation of macrophage differentiation; IMP:UniProtKB.
DR   GO; GO:0060545; P:positive regulation of necroptotic process; IMP:UniProtKB.
DR   GO; GO:0010940; P:positive regulation of necrotic cell death; IMP:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; TAS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0051291; P:protein heterooligomerization; IMP:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0070926; P:regulation of ATP:ADP antiporter activity; IMP:BHF-UCL.
DR   GO; GO:1902041; P:regulation of extrinsic apoptotic signaling pathway via death domain receptors; TAS:Reactome.
DR   GO; GO:0060544; P:regulation of necroptotic process; TAS:Reactome.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IMP:BHF-UCL.
DR   GO; GO:0097343; P:ripoptosome assembly; IMP:UniProtKB.
DR   GO; GO:1901026; P:ripoptosome assembly involved in necroptotic process; IBA:GO_Central.
DR   GO; GO:0070231; P:T cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR025735; RHIM_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF12721; RHIM; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Kinase; Membrane; Necrosis;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1    671       Receptor-interacting serine/threonine-
FT                                protein kinase 1.
FT                                /FTId=PRO_0000086606.
FT   DOMAIN       17    289       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      583    669       Death. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00064}.
FT   NP_BIND      23     31       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      290    582       Interaction with SQSTM1.
FT                                {ECO:0000269|PubMed:10356400}.
FT   MOTIF       531    547       RIP homotypic interaction motif (RHIM).
FT   COMPBIAS    411    414       Poly-Arg.
FT   ACT_SITE    138    138       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      49     49       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        324    325       Cleavage; by caspase-8.
FT   MOD_RES       6      6       Phosphoserine.
FT                                {ECO:0000269|PubMed:18408713}.
FT   MOD_RES      20     20       Phosphoserine; by autocatalysis.
FT                                {ECO:0000255}.
FT   MOD_RES      25     25       Phosphoserine.
FT                                {ECO:0000269|PubMed:18408713}.
FT   MOD_RES     161    161       Phosphoserine; by RIPK3 and
FT                                autocatalysis. {ECO:0000255}.
FT   MOD_RES     166    166       Phosphoserine; by autocatalysis.
FT                                {ECO:0000255}.
FT   MOD_RES     303    303       Phosphoserine.
FT                                {ECO:0000269|PubMed:18408713}.
FT   MOD_RES     320    320       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:18408713}.
FT   MOD_RES     333    333       Phosphoserine.
FT                                {ECO:0000269|PubMed:18408713}.
FT   MOD_RES     384    384       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15144186}.
FT   VAR_SEQ     108    153       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_037690.
FT   VARIANT      64     64       A -> V (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs774996232).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041039.
FT   VARIANT      81     81       V -> I (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs758268804).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041040.
FT   VARIANT     220    220       A -> V (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs759012409).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041041.
FT   VARIANT     234    234       E -> K (in dbSNP:rs17548383).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021109.
FT   VARIANT     404    404       A -> S (in dbSNP:rs34872409).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041042.
FT   VARIANT     438    438       A -> V (in dbSNP:rs3173519).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:7538908,
FT                                ECO:0000269|PubMed:8612133}.
FT                                /FTId=VAR_058285.
FT   VARIANT     443    443       A -> V (in dbSNP:rs35722193).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041043.
FT   VARIANT     569    569       A -> V (in dbSNP:rs55861377).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041044.
FT   MUTAGEN      45     45       K->A: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:8612133}.
FT   MUTAGEN     161    161       S->A: Decreases RIPK1 kinase activity.
FT                                {ECO:0000269|PubMed:18408713}.
FT   MUTAGEN     161    161       S->E: No effect on RIPK1
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:18408713}.
FT   MUTAGEN     324    324       D->K: Abolishes cleavage by caspase-8.
FT                                {ECO:0000269|PubMed:10521396}.
FT   MUTAGEN     377    377       K->R: Abolishes RIP-mediated NF-Kappa-B
FT                                activation.
FT                                {ECO:0000269|PubMed:16603398}.
FT   CONFLICT    258    258       R -> I (in Ref. 3; BAG36858).
FT                                {ECO:0000305}.
FT   CONFLICT    286    286       R -> S (in Ref. 3; BAG36858).
FT                                {ECO:0000305}.
FT   CONFLICT    514    514       T -> S (in Ref. 8; AAC50137).
FT                                {ECO:0000305}.
FT   HELIX        14     16       {ECO:0000244|PDB:4ITJ}.
FT   STRAND       17     19       {ECO:0000244|PDB:5HX6}.
FT   STRAND       20     22       {ECO:0000244|PDB:4ITJ}.
FT   TURN         26     28       {ECO:0000244|PDB:4ITI}.
FT   STRAND       30     36       {ECO:0000244|PDB:4ITJ}.
FT   TURN         37     39       {ECO:0000244|PDB:4ITJ}.
FT   STRAND       40     51       {ECO:0000244|PDB:4ITJ}.
FT   HELIX        54     56       {ECO:0000244|PDB:4ITJ}.
FT   HELIX        57     68       {ECO:0000244|PDB:4ITJ}.
FT   STRAND       78     84       {ECO:0000244|PDB:4ITJ}.
FT   STRAND       87     93       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       100    104       {ECO:0000244|PDB:4ITJ}.
FT   STRAND      106    108       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       112    131       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       141    143       {ECO:0000244|PDB:4ITJ}.
FT   STRAND      144    146       {ECO:0000244|PDB:4ITJ}.
FT   STRAND      152    154       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       163    168       {ECO:0000244|PDB:4ITJ}.
FT   STRAND      171    173       {ECO:0000244|PDB:4ITH}.
FT   HELIX       190    192       {ECO:0000244|PDB:4NEU}.
FT   HELIX       195    197       {ECO:0000244|PDB:4ITJ}.
FT   STRAND      201    203       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       207    223       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       234    242       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       249    251       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       258    267       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       272    274       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       278    292       {ECO:0000244|PDB:4ITJ}.
FT   HELIX       294    296       {ECO:0000244|PDB:4NEU}.
FT   HELIX       297    309       {ECO:0000244|PDB:4NEU}.
FT   TURN        310    312       {ECO:0000244|PDB:4NEU}.
SQ   SEQUENCE   671 AA;  75931 MW;  976E2428D525A9B2 CRC64;
     MQPDMSLNVI KMKSSDFLES AELDSGGFGK VSLCFHRTQG LMIMKTVYKG PNCIEHNEAL
     LEEAKMMNRL RHSRVVKLLG VIIEEGKYSL VMEYMEKGNL MHVLKAEMST PLSVKGRIIL
     EIIEGMCYLH GKGVIHKDLK PENILVDNDF HIKIADLGLA SFKMWSKLNN EEHNELREVD
     GTAKKNGGTL YYMAPEHLND VNAKPTEKSD VYSFAVVLWA IFANKEPYEN AICEQQLIMC
     IKSGNRPDVD DITEYCPREI ISLMKLCWEA NPEARPTFPG IEEKFRPFYL SQLEESVEED
     VKSLKKEYSN ENAVVKRMQS LQLDCVAVPS SRSNSATEQP GSLHSSQGLG MGPVEESWFA
     PSLEHPQEEN EPSLQSKLQD EANYHLYGSR MDRQTKQQPR QNVAYNREEE RRRRVSHDPF
     AQQRPYENFQ NTEGKGTAYS SAASHGNAVH QPSGLTSQPQ VLYQNNGLYS SHGFGTRPLD
     PGTAGPRVWY RPIPSHMPSL HNIPVPETNY LGNTPTMPFS SLPPTDESIK YTIYNSTGIQ
     IGAYNYMEIG GTSSSLLDST NTNFKEEPAA KYQAIFDNTT SLTDKHLDPI RENLGKHWKN
     CARKLGFTQS QIDEIDHDYE RDGLKEKVYQ MLQKWVMREG IKGATVGKLA QALHQCSRID
     LLSSLIYVSQ N
//
